Form 4: iRhythm Technologies Executive Granted Significant Restricted Stock Units

iRhythm Technologies' EVP of Strategy & Corporate Development, Sean Clinton Freeman, was granted 6,761 restricted stock units, vesting over four years starting July 2026.

Summary

• Sean Clinton Freeman, Executive Vice President of Strategy & Corporate Development at iRhythm Technologies, Inc. (IRTC), acquired 6,761 shares of Common Stock.
• The acquisition was in the form of Restricted Stock Units (RSUs) with an acquisition price of $0 per unit.
• The transaction date for this grant was July 1, 2025.
• These RSUs represent a contingent right to receive one share of the Issuer's Common Stock per unit.
• The vesting schedule for these RSUs is 25% on July 1, 2026, and an additional 25% on each subsequent one-year anniversary, contingent upon Mr. Freeman's continued service as a service provider through each vesting date.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a key executive is a positive signal for executive retention and alignment of interests with shareholders, indicating stability in leadership and a commitment to long-term value creation.

Positives

• The grant of restricted stock units to a key executive like the EVP of Strategy & Corporate Development serves as a strong incentive for long-term retention.
• This form of equity compensation aligns the executive's financial interests directly with the long-term performance and shareholder value of iRhythm Technologies.

Risks

• The vesting of the restricted stock units is subject to the reporting person continuing as a service provider through each vesting date, meaning the executive must remain employed to realize the full value of the grant.

Future Outlook

The vesting schedule of the restricted stock units extends through July 2029, indicating a long-term commitment and incentive structure for the executive, aligning their future performance with the company's success.

Industry Context

The granting of restricted stock units (RSUs) is a common and widely accepted practice in the technology and medical device industries for executive compensation. It serves as a key tool for attracting, retaining, and motivating top talent by providing a direct stake in the company's future performance.

Comparison to Industry Standards

• Granting RSUs as a form of executive compensation is a standard practice across the healthcare technology sector, including companies like Dexcom, Insulet, and Tandem Diabetes Care, which frequently use equity awards to incentivize their leadership.
• The vesting schedule, typically over three to four years, is also consistent with industry norms designed to encourage long-term commitment and performance from executives.

Stakeholder Impact

• Shareholders: The RSU grant aligns the executive's long-term interests with shareholder value creation, potentially leading to more focused strategic decisions.
• Employees (Executive): The grant provides significant long-term compensation and incentive for the executive to remain with the company and contribute to its success.

Next Steps

• The vesting of 25% of the granted RSUs will occur on July 1, 2026, and annually thereafter, subject to the executive's continued service.

Key Dates

Keywords

iRhythm Technologies, IRTC, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Sean Clinton Freeman, Equity Grant